Cargando…

Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: The therapeutic effects of tacrolimus (TAC) versus cyclophosphamide (CTX) were not fully illustrated for patients with idiopathic membranous nephropathy (IMN). METHODS: The PubMed, EmBase, Cochrane library, and CNKI were systematically searched throughout March 2020 for randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Haiting, Liang, Zhao, Zheng, Xintong, Qing, Qin, Du, Xiuri, Tang, Zhiming, Wei, Meili, Wang, Chen, Zhong, Qiuhong, Lin, Xu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158268/ https://www.ncbi.nlm.nih.gov/pubmed/34016023 http://dx.doi.org/10.1080/0886022X.2021.1914655

Ejemplares similares

Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2021)

Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
por: Zou, Honghong, et al.
Publicado: (2019)

Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis
por: Lin, Wenshan, et al.
Publicado: (2019)

Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
por: Ramachandran, Raja, et al.
Publicado: (2017)

Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy
por: Cui, W., et al.
Publicado: (2017)

Evaluating tacrolimus treatment in idiopathic membranous nephropathy in a cohort of 408 patients
por: Qin, Hua-Zhang, et al.
Publicado: (2017)

Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy
por: Shang, Shun-Lai, et al.
Publicado: (2018)

Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis
por: Gong, Lifeng, et al.
Publicado: (2021)

Efficacy and Safety of Cyclosporine versus Tacrolimus in Steroid and Cyclophosphamide Resistant Nephrotic Syndrome: A Prospective Study
por: Prasad, N., et al.
Publicado: (2018)

Rituximab versus steroids and cyclophosphamide for the treatment of primary membranous nephropathy: protocol of a pilot randomised controlled trial
por: Scolari, Francesco, et al.
Publicado: (2019)

A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study
por: Rojas-Rivera, Jorge, et al.
Publicado: (2015)

Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy
por: Lv, Wei, et al.
Publicado: (2021)

Transforming growth factor-β1-induced podocyte injury is associated with increased microRNA-155 expression, enhanced inflammatory responses and MAPK pathway activation
por: Zheng, Xintong, et al.
Publicado: (2021)

Electron-Dense Deposition Patterns and the Outcomes of Nephrotic Idiopathic Membranous Nephropathy Treated with Tacrolimus in Chinese Adults
por: Xiang, Xin, et al.
Publicado: (2021)

Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy
por: Wang, Qi, et al.
Publicado: (2021)

The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy
por: Liang, Qian, et al.
Publicado: (2017)

Intravenous cyclophosphamide and oral prednisolone is a safe and effective treatment option for idiopathic membranous nephropathy
por: Mathrani, Vinod, et al.
Publicado: (2017)

Mycophenolate mofetil and tacrolimus versus tacrolimus alone for the treatment of idiopathic membranous glomerulonephritis: a randomised controlled trial
por: Nikolopoulou, Aikaterini, et al.
Publicado: (2019)

Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study
por: Liu, Shanshan, et al.
Publicado: (2015)

Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
por: Cortazar, Frank B., et al.
Publicado: (2017)

Comparison of cyclophosphamide and calcineurin inhibitors for idiopathic membranous nephropathy: A protocol for systematic review and meta-analysis
por: Li, Kang, et al.
Publicado: (2022)

Comparison of prognostic, clinical, and renal histopathological characteristics of overlapping idiopathic membranous nephropathy and IgA nephropathy versus idiopathic membranous nephropathy
por: Chen, Xinxin, et al.
Publicado: (2017)

Long-Term Safety, Clinical and Immunological Outcomes in Primary Membranous Nephropathy with Severe Renal Impairment Treated with Cyclophosphamide and Steroid-Based Regimen
por: Ragy, Omar, et al.
Publicado: (2023)

Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy
por: Zhang, Chengning, et al.
Publicado: (2020)

Phospholipase‐A2 receptor antibody, 24 hours proteinuria, and serum albumin as indicators of cyclophosphamide efficacy in idiopathic membranous nephropathy
por: Xiao, Chunying, et al.
Publicado: (2020)

Treatment of idiopathic membranous nephropathy in adults: KDIGO 2012, cyclophosphamide and cyclosporine A are out, rituximab is the new normal
por: Rojas-Rivera, Jorge Enrique, et al.
Publicado: (2019)

Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome
por: Saito, Takao, et al.
Publicado: (2016)

Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study
por: Chen, Shasha, et al.
Publicado: (2020)

Tacrolimus-induced epilepsy with primary membranous nephropathy: A case report
por: Yang, Yan, et al.
Publicado: (2021)

Helper T Cells in Idiopathic Membranous Nephropathy
por: Zhao, Qihan, et al.
Publicado: (2021)

Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life
por: Wang, Li, et al.
Publicado: (2022)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Two cases of idiopathic membranous nephropathy treated with rituximab
por: Young Yoon, Jae, et al.
Publicado: (2013)

Association of gut microbiota with idiopathic membranous nephropathy
por: Li, Mengfei, et al.
Publicado: (2022)

Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels
por: Xue, Cheng, et al.
Publicado: (2023)

Chapter 7: Idiopathic membranous nephropathy
Publicado: (2012)

Treatment with rituximab in idiopathic membranous nephropathy
por: Fiorentino, Marco, et al.
Publicado: (2016)

Calcineurin inhibitors or cyclophosphamide in the treatment of membranous nephropathy superimposed with FSGS lesions: a retrospective study from China
por: He, Hong-Guang, et al.
Publicado: (2023)

Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide
por: Zhang, Xuebing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0llpa23j3oa83v7mgpnfc16e58